{"id":2109,"date":"2018-07-20T09:14:56","date_gmt":"2018-07-20T14:14:56","guid":{"rendered":"https:\/\/restruct-lgmd-2021.pantheonsite.io\/?p=2109"},"modified":"2018-07-20T09:14:56","modified_gmt":"2018-07-20T14:14:56","slug":"lgmd-researcher-emerson","status":"publish","type":"post","link":"https:\/\/www.lgmd-info.org\/tr\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/","title":{"rendered":"LGMD ARA\u015eTIRMACISI: Charles P. Emerson, Jr., Ph.D."},"content":{"rendered":"<p>LGMD \"Ara\u015ft\u0131rma \u00dczerine Spotlight R\u00f6portaj\u0131\"<\/p>\n<p><span style=\"color: #000000;\"><strong>LGMD ARA\u015eTIRMACISI:<\/strong> Charles P. Emerson, Jr., Ph.D.<a style=\"color: #000000;\" href=\"https:\/\/www.lgmd-info.org\/wp-content\/uploads\/2018\/07\/Emerson-Charles.png\"><img decoding=\"async\" class=\"lazyload size-medium wp-image-2108 alignright\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27300%27%20height%3D%27225%27%20viewBox%3D%270%200%20300%20225%27%3E%3Crect%20width%3D%27300%27%20height%3D%27225%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-orig-src=\"https:\/\/www.lgmd-info.org\/wp-content\/uploads\/2018\/07\/Emerson-Charles-300x225.png\" alt=\"\" width=\"300\" height=\"225\" \/><\/a><\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>Ba\u011fl\u0131l\u0131k:\u00a0 <\/strong>N\u00f6roloji Profes\u00f6r\u00fc; UMMS Wellstone Musk\u00fcler Distrofi Program\u0131 Direkt\u00f6r\u00fc<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000;\"><strong>\u015eu anki pozisyonunuza gelmek i\u00e7in hangi e\u011fitim ve \u00f6\u011fretimi ald\u0131n\u0131z?<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Lisans e\u011fitimim biyoloji\/biyokimya alan\u0131ndayd\u0131 ve kas proteini biyokimyas\u0131 \u00fczerine \u00fc\u00e7 yaz ara\u015ft\u0131rma yapmay\u0131 i\u00e7eriyordu; bu, g\u00f6zlerimi ara\u015ft\u0131rma ke\u015ffinin heyecan\u0131na a\u00e7an d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir deneyim ve <\/span>kur\u015fun<span style=\"color: #000000;\"> Beni hala heyecanland\u0131ran biyomedikal ara\u015ft\u0131rma alan\u0131nda kariyer yapmaya y\u00f6neltti. Y\u00fcksek lisans derecem ve ara\u015ft\u0131rma e\u011fitimim <\/span>oldu<span style=\"color: #000000;\"> molek\u00fcler ve h\u00fccre biyolojisinin geli\u015fmekte olan alanlar\u0131nda <\/span>uygulama<span style=\"color: #000000;\"> Geli\u015fmekte olan deniz kestanesi embriyosunu model sistem olarak kullanarak geli\u015fimsel gen d\u00fczenleme mekanizmalar\u0131na molek\u00fcler biyoloji yakla\u015f\u0131mlar\u0131. Doktora sonras\u0131 e\u011fitimim, kas biyolojisine olan lisans ilgimi ve geli\u015fimsel gen d\u00fczenlemesine olan lisans\u00fcst\u00fc ilgimi bir araya getirerek <\/span>uzun kariyer<span style=\"color: #000000;\"> Kas h\u00fccre k\u00fclt\u00fcr\u00fc ve Drosophila, ku\u015f ve fare genetik ve embriyolojik hayvan modelleri ve h\u00fccre sinyali, gen klonlama ve DNA dizilimi, transkripsiyonel d\u00fczenleme ve h\u00fccre yeniden programlama gibi deneysel yakla\u015f\u0131mlar dahil olmak \u00fczere \u00e7e\u015fitli biyolojik sistemler kullanarak kas geli\u015fimi ve farkl\u0131la\u015fmas\u0131n\u0131n temel mekanizmalar\u0131n\u0131 ara\u015ft\u0131ran ara\u015ft\u0131rma yolculu\u011fu. Yakla\u015f\u0131k 10 y\u0131l \u00f6nce, ara\u015ft\u0131rmalar\u0131m\u0131 tamamen insan kas geli\u015fimi ve kas distrofisine y\u00f6nlendirmek i\u00e7in ilham ald\u0131m.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000;\"><strong>Sizi ara\u015ft\u0131rma alan\u0131nda kariyer yapmaya ve \u00f6zellikle kas distrofisi \u00fczerine \u00e7al\u0131\u015fmaya y\u00f6nlendiren neydi?<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">10 y\u0131l \u00f6ncesine kadar, ara\u015ft\u0131rmalar\u0131m sadece embriyonik h\u00fccrelerin genomlar\u0131n\u0131 programlayan gen d\u00fczenleyici mekanizmalar\u0131 anlamaya odaklan\u0131yordu. <\/span>olmak<span style=\"color: #000000;\"> kas k\u00f6k h\u00fccreleri farkl\u0131la\u015fmalar\u0131 s\u0131ras\u0131nda kas genlerini ifade eder. \u00c7al\u0131\u015fmalar\u0131m NIH ve Musk\u00fcler Distrofi Derne\u011fi taraf\u0131ndan, bu temel bilim bilgisinin nihayetinde insan hastal\u0131\u011f\u0131n\u0131 ve terap\u00f6tiklerini anlamaya yol a\u00e7aca\u011f\u0131 \u00f6ng\u00f6r\u00fcs\u00fcyle c\u00f6mert\u00e7e desteklendi. Ara\u015ft\u0131rma program\u0131m\u0131 insan kas biyolojisi ve hastal\u0131klar\u0131na yeniden odaklama karar\u0131m k\u0131smen ilham, k\u0131smen de zaman\u0131n geldi\u011fini kabul etmekti. <\/span>gel<span style=\"color: #000000;\"> Temel bilim uzmanl\u0131\u011f\u0131m\u0131 kullanarak bir katk\u0131da bulunmak. \u00d6nce ilham kayna\u011f\u0131. Bu, fiziksel engelli insanlar ve ailelerle olan ki\u015fisel ili\u015fkimden geliyor. K\u0131z\u0131m, do\u011fum s\u0131ras\u0131nda ge\u00e7irdi\u011fi beyin hasar\u0131 sonucunda ileri derecede fiziksel engelli. Motorlu tekerlekli sandalye ve bilgisayar gibi yeni icatlar\u0131n b\u00fcy\u00fck \u00f6l\u00e7\u00fcde kolayla\u015ft\u0131rd\u0131\u011f\u0131 anlaml\u0131 bir hayat kurma konusundaki azmi ve kararl\u0131l\u0131\u011f\u0131 i\u00e7in minnettar\u0131m. K\u0131z\u0131m, kas biyolojisi konusundaki uzmanl\u0131\u011f\u0131m\u0131n bir g\u00fcn benim i\u00e7in de m\u00fcmk\u00fcn olabilece\u011finin s\u00fcrekli bir hat\u0131rlat\u0131c\u0131s\u0131 oldu. <\/span>Yard\u0131m<span style=\"color: #000000;\"> kas engelli \u00e7ocuklar\u0131 ve yeti\u015fkinleri takdir etmek <\/span>g\u00f6r\u00fcn\u00fc\u015fte k\u00fc\u00e7\u00fck iyile\u015ftirmelerin<span style=\"color: #000000;\"> kas fonksiyonlar\u0131ndaki iyile\u015fme, fiziksel engellilerin ya\u015fam kalitesi \u00fczerinde b\u00fcy\u00fck bir etkiye sahip olabilir. Derken, 10 y\u0131l \u00f6nce bir \u00f6\u011fleden sonra, Daniel Perez ad\u0131nda kas distrofisi olan bir adam <\/span>laboratuvar<span style=\"color: #000000;\"> Tekerlekli sandalyesinde oturuyordu ve bana olduk\u00e7a iyi bir kas biyolo\u011fu olan benim neden onun kas hastal\u0131\u011f\u0131 \u00fczerinde \u00e7al\u0131\u015fmad\u0131\u011f\u0131m\u0131 sordu. Onun hastal\u0131\u011f\u0131 olan FSHD'yi hi\u00e7 duymam\u0131\u015ft\u0131m ve \"kas uzmanl\u0131\u011f\u0131ma\" ra\u011fmen kas distrofilerinin hi\u00e7biri hakk\u0131nda neredeyse hi\u00e7bir \u015fey bilmedi\u011fim ger\u00e7e\u011fiyle \u015fok oldum.  Daniel bana kas distrofisi ara\u015ft\u0131rmalar\u0131 d\u00fcnyas\u0131n\u0131n kap\u0131lar\u0131n\u0131 ard\u0131na kadar a\u00e7t\u0131. FSHD ve musk\u00fcler distrofi ara\u015ft\u0131rmalar\u0131 hakk\u0131nda son derece bilgiliydi, distrofileri ara\u015ft\u0131rmak ve belirli ara\u015ft\u0131rma \u00f6nceliklerini tan\u0131mlamak i\u00e7in \u00f6nde gelen kas ara\u015ft\u0131rmac\u0131lar\u0131ndan olu\u015fan bir a\u011f kuruyor ve e\u011fitiyordu ve NIH finansman\u0131 ve FSHD hastalar\u0131n\u0131n ve aile \u00fcyelerinin ara\u015ft\u0131rmalara kat\u0131lmas\u0131 i\u00e7in Kongre'de son derece sesli ve etkili bir savunucuydu.  Ayr\u0131ca, kas k\u00f6k h\u00fccre biyolojisi ve gen d\u00fczenlemesi konusundaki uzmanl\u0131\u011f\u0131m sayesinde kas temel bilimimi insan kas hastal\u0131\u011f\u0131 modellerine d\u00f6n\u00fc\u015ft\u00fcrmenin do\u011fru zaman oldu\u011funu fark ettim; bu uzmanl\u0131k FSHD ve \u015fimdi LGMD kas distrofilerinin insan h\u00fccre modellerini geli\u015ftirmemi sa\u011flad\u0131 ve belirli distrofilerin molek\u00fcler patolojisinin yeni bir d\u00fczeyde anla\u015f\u0131lmas\u0131n\u0131 sa\u011flad\u0131 ve hayvan hastal\u0131\u011f\u0131 modellerinin \u00e7ok \u00f6tesinde, hastadan t\u00fcretilen kas kullan\u0131larak terap\u00f6tiklerin geli\u015ftirilmesi i\u00e7in deneysel platformlar sa\u011flad\u0131. Ge\u00e7ti\u011fimiz 10 y\u0131l boyunca, ara\u015ft\u0131rmalar\u0131m tamamen insan kas biyolojisi ve kas distrofilerine, ba\u015flang\u0131\u00e7ta FSHD ve daha yak\u0131n zamanda LGMD2i ve 2G dahil olmak \u00fczere LGMD'lere yeniden odakland\u0131. FSHD'de oldu\u011fu gibi, LGMD'lerle ilgili ara\u015ft\u0131rmam da tutkulu ve bilin\u00e7li seslere sahip hastalardan ve savunuculardan ilham ald\u0131 ve kendi hastal\u0131klar\u0131na y\u00f6nelik tedaviler i\u00e7in umutlar besledi. <\/span>ya\u015fam s\u00fcreleri\u0307<span style=\"color: #000000;\">.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000;\"><strong>Hangi konular \u00fczerinde \u00e7al\u0131\u015f\u0131yorsunuz?<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Bug\u00fcn, ara\u015ft\u0131rma laboratuvar\u0131m, yetenekli ve i\u015fbirlik\u00e7i akademik ve end\u00fcstri ortaklar\u0131, klinisyenler ve hastalardan olu\u015fan bir kadro ile birlikte FSHD, LGMD2i tedavisi i\u00e7in ila\u00e7, k\u00f6k h\u00fccre ve gen d\u00fczeltme tedavilerinin klinik \u00f6ncesi geli\u015ftirme ve do\u011frulama \u00e7al\u0131\u015fmalar\u0131n\u0131 s\u00fcrd\u00fcrmektedir. <\/span>ve<span style=\"color: #000000;\"> LGMD2G.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000;\"><strong>\u00c7al\u0131\u015fman\u0131z hastalara nas\u0131l yard\u0131mc\u0131 olacak? Do\u011fas\u0131 gere\u011fi daha bilimsel mi yoksa LGMD'ler veya genel olarak MD'ler i\u00e7in bir tedavi olabilir mi?<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Kas distrofisi tedavileri geli\u015ftirmeye y\u00f6nelik ara\u015ft\u0131rmalar\u0131m, hastalar\u0131n ve aile \u00fcyelerinin h\u00fccrelerini ve kas dokular\u0131n\u0131 benim gibi ara\u015ft\u0131rmac\u0131lara hevesle ba\u011f\u0131\u015flamalar\u0131 sayesinde m\u00fcmk\u00fcn olmu\u015ftur; bu da insan hastal\u0131\u011f\u0131 patolojisini anlamak ve insan hastal\u0131\u011f\u0131n\u0131n hayvan modellerini kullanarak m\u00fcmk\u00fcn olmayan gelecekteki klinik deneyleri desteklemek i\u00e7in ila\u00e7lar, k\u00f6k h\u00fccreler ve gen d\u00fczeltme ara\u00e7lar\u0131 ve hastal\u0131k biyobelirte\u00e7leri geli\u015ftirmeyi m\u00fcmk\u00fcn k\u0131lmaktad\u0131r. Hedefimiz <\/span>geli\u015ftirilir<span style=\"color: #000000;\"> FSHD, LGMD2i ve LGMD2G hastalar\u0131 i\u00e7in klinik \u00e7al\u0131\u015fmalarda ve klinik kullan\u0131mda de\u011ferlendirilmek \u00fczere terap\u00f6tikler.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000;\"><strong>Hastalar\u0131n ve LGMD ile ilgilenen di\u011fer ki\u015filerin ara\u015ft\u0131rma hakk\u0131nda (kendi projeleriniz ve genel olarak alan hakk\u0131nda) ne bilmelerini istersiniz?<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Kas distrofisi ara\u015ft\u0131rmalar\u0131, klinik testler i\u00e7in tedavilerin geli\u015ftirilmesine do\u011fru h\u0131zla ilerlemektedir, bu nedenle hastalar ve aileler umutlu, tutkulu ve bilgili savunucular olmal\u0131 ve yeni ortaya \u00e7\u0131kmaya ba\u015flayan klinik deneylerde terap\u00f6tikleri test etmek i\u00e7in bilim insanlar\u0131yla ortak olmal\u0131d\u0131r.  44 genetik kas distrofisinin her birinin kendine \u00f6zg\u00fc terap\u00f6tik zorluklar\u0131 vard\u0131r. Bununla birlikte, gen terapisi, k\u00f6k h\u00fccre terapisi, CRISPR gen d\u00fczeltme terapisi, RNA terapisi ve geli\u015fmi\u015f k\u00fc\u00e7\u00fck molek\u00fcll\u00fc ila\u00e7lar da dahil olmak \u00fczere 10 y\u0131l \u00f6nce duyulmam\u0131\u015f yenilik\u00e7i terap\u00f6tik modlar\u0131n geli\u015ftirilmesiyle te\u015fvik edilen ke\u015fif h\u0131z\u0131, t\u00fcm kas distrofilerinin tedavisi i\u00e7in terap\u00f6tik se\u00e7enekleri \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rmaktad\u0131r. Bununla birlikte, i\u015flevsel olarak karma\u015f\u0131k olan ve v\u00fccudun her yerine da\u011f\u0131lm\u0131\u015f olan kaslara terap\u00f6tiklerin ula\u015ft\u0131r\u0131lmas\u0131 ve iyile\u015ftirilmi\u015f kas fonksiyonu i\u00e7in klinik sonu\u00e7lar\u0131 do\u011fru ve h\u0131zl\u0131 bir \u015fekilde \u00f6l\u00e7mek i\u00e7in klinik \u00e7al\u0131\u015fma protokollerinin geli\u015ftirilmesi gibi \u00f6nemli zorluklar devam etmektedir ve bu da hasta-ara\u015ft\u0131rmac\u0131 ortakl\u0131\u011f\u0131 gerektirmektedir. Kas hastal\u0131\u011f\u0131n\u0131n tedavisi hakk\u0131nda hala \u00f6\u011frenilecek \u00e7ok \u015fey vard\u0131r, ancak farkl\u0131 distrofiler \u00fczerinde \u00e7al\u0131\u015fan ara\u015ft\u0131rmac\u0131lar ve hastalar aktif olarak birbirlerinin \u00e7al\u0131\u015fmalar\u0131ndan ve deneyimlerinden \u00f6\u011frenerek ke\u015fif h\u0131z\u0131n\u0131 ve ila\u00e7 geli\u015ftirme h\u0131z\u0131n\u0131 art\u0131rmaktad\u0131r. Hastalar\u0131n tutkusu ve devam eden ara\u015ft\u0131rma ve klinik deneylere kat\u0131l\u0131m\u0131 ilerleme i\u00e7in \u00e7ok \u00f6nemlidir.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>Bu alanda \u00e7al\u0131\u015fmaya devam etmek i\u00e7in size ilham veren nedir? <\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Umudum ve ilham kayna\u011f\u0131m, \u00f6n\u00fcm\u00fczdeki be\u015f y\u0131l i\u00e7inde LGMD kas distrofilerine y\u00f6nelik tedavilerin ortaya \u00e7\u0131kacak olmas\u0131d\u0131r.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000;\"><strong>Hastalar sizi nas\u0131l te\u015fvik edebilir ve \u00e7al\u0131\u015fmalar\u0131n\u0131za nas\u0131l yard\u0131mc\u0131 olabilir?<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Hastalar, ara\u015ft\u0131rma ve klinik \u00e7al\u0131\u015fmalara kat\u0131l\u0131mlar\u0131, ara\u015ft\u0131rmac\u0131lara, klinisyenlere ve e\u011fitim g\u00f6ren bilim insanlar\u0131na musk\u00fcler distrofi ara\u015ft\u0131rmalar\u0131na kat\u0131lmalar\u0131 ve ilham vermeleri ve ilerlemenin anahtar\u0131 olan ara\u015ft\u0131rma finansman\u0131 i\u00e7in kamu, NIH ve vak\u0131flar nezdinde savunuculuk yapmalar\u0131 yoluyla tedavinin geli\u015ftirilmesinde \u00f6nemli ortaklard\u0131r.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>* * * LGMD konusunda fark\u0131ndal\u0131k yaratmaya yard\u0131mc\u0131 olmak i\u00e7in l\u00fctfen bu g\u00f6nderiyi BE\u011eEN\u0130N, YORUM YAPIN ve PAYLA\u015eIN!<\/p>\n<p>* Limb Girdle Muscular Dystrophy (LGMD) hakk\u0131nda daha fazla bilgi edinmek veya daha fazla \"Spotlight Interviews\" okumak i\u00e7in l\u00fctfen web sitemizi ziyaret edin <a href=\"https:\/\/www.lgmd-info.org\/tr\/\">https:\/\/www.lgmd-info.org\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>LGMD \u201cSpotlight Interview on Research\u201d LGMD RESEARCHER: Charles P. Emerson, [&hellip;]<\/p>","protected":false},"author":1,"featured_media":2108,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[91,92],"tags":[],"class_list":["post-2109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-researcher-interview","category-researcher"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D. - LGMD Awareness Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lgmd-info.org\/tr\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D. - LGMD Awareness Foundation\" \/>\n<meta property=\"og:description\" content=\"LGMD \u201cSpotlight Interview on Research\u201d LGMD RESEARCHER: Charles P. Emerson, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lgmd-info.org\/tr\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/\" \/>\n<meta property=\"og:site_name\" content=\"LGMD Awareness Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LGMDawareness\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-20T14:14:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lgmd-info.org\/wp-content\/uploads\/2021\/06\/LGMD-Logo_1200X630.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"dooley\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@LgmdAwareness\" \/>\n<meta name=\"twitter:site\" content=\"@LgmdAwareness\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"dooley\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/\"},\"author\":{\"name\":\"dooley\",\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#\/schema\/person\/007755074875959ad5503c1c969678c7\"},\"headline\":\"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D.\",\"datePublished\":\"2018-07-20T14:14:56+00:00\",\"dateModified\":\"2018-07-20T14:14:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/\"},\"wordCount\":1218,\"publisher\":{\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"LGMD Researcher - Interviews\",\"RESEARCHER\"],\"inLanguage\":\"tr-TR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/\",\"url\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/\",\"name\":\"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D. - LGMD Awareness Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2018-07-20T14:14:56+00:00\",\"dateModified\":\"2018-07-20T14:14:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#breadcrumb\"},\"inLanguage\":\"tr-TR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr-TR\",\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lgmd-info.org\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#website\",\"url\":\"https:\/\/www.lgmd-info.org\/de\/\",\"name\":\"LGMD Awareness Foundation\",\"description\":\"Information Hub for the LGMD community\",\"publisher\":{\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lgmd-info.org\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr-TR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#organization\",\"name\":\"LGMD Awareness Foundation, Inc.\",\"url\":\"https:\/\/www.lgmd-info.org\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr-TR\",\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lgmd-info.org\/wp-content\/uploads\/2021\/02\/LGMD_Logo.png\",\"contentUrl\":\"https:\/\/lgmd-info.org\/wp-content\/uploads\/2021\/02\/LGMD_Logo.png\",\"width\":208,\"height\":61,\"caption\":\"LGMD Awareness Foundation, Inc.\"},\"image\":{\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LGMDawareness\/\",\"https:\/\/x.com\/LgmdAwareness\",\"https:\/\/www.instagram.com\/lgmdawareness\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#\/schema\/person\/007755074875959ad5503c1c969678c7\",\"name\":\"dooley\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr-TR\",\"@id\":\"https:\/\/www.lgmd-info.org\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c87b3b784fd4c1975884b6c3eab282b5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c87b3b784fd4c1975884b6c3eab282b5?s=96&d=mm&r=g\",\"caption\":\"dooley\"},\"sameAs\":[\"https:\/\/live-lgmd-2021.pantheonsite.io\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D. - LGMD Awareness Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lgmd-info.org\/tr\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/","og_locale":"tr_TR","og_type":"article","og_title":"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D. - LGMD Awareness Foundation","og_description":"LGMD \u201cSpotlight Interview on Research\u201d LGMD RESEARCHER: Charles P. Emerson, [&hellip;]","og_url":"https:\/\/www.lgmd-info.org\/tr\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/","og_site_name":"LGMD Awareness Foundation","article_publisher":"https:\/\/www.facebook.com\/LGMDawareness\/","article_published_time":"2018-07-20T14:14:56+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.lgmd-info.org\/wp-content\/uploads\/2021\/06\/LGMD-Logo_1200X630.png","type":"image\/png"}],"author":"dooley","twitter_card":"summary_large_image","twitter_creator":"@LgmdAwareness","twitter_site":"@LgmdAwareness","twitter_misc":{"Written by":"dooley","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#article","isPartOf":{"@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/"},"author":{"name":"dooley","@id":"https:\/\/www.lgmd-info.org\/de\/#\/schema\/person\/007755074875959ad5503c1c969678c7"},"headline":"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D.","datePublished":"2018-07-20T14:14:56+00:00","dateModified":"2018-07-20T14:14:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/"},"wordCount":1218,"publisher":{"@id":"https:\/\/www.lgmd-info.org\/de\/#organization"},"image":{"@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage"},"thumbnailUrl":"","articleSection":["LGMD Researcher - Interviews","RESEARCHER"],"inLanguage":"tr-TR"},{"@type":"WebPage","@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/","url":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/","name":"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D. - LGMD Awareness Foundation","isPartOf":{"@id":"https:\/\/www.lgmd-info.org\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage"},"image":{"@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage"},"thumbnailUrl":"","datePublished":"2018-07-20T14:14:56+00:00","dateModified":"2018-07-20T14:14:56+00:00","breadcrumb":{"@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#breadcrumb"},"inLanguage":"tr-TR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/"]}]},{"@type":"ImageObject","inLanguage":"tr-TR","@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/www.lgmd-info.org\/ko\/researcher-interview\/2018\/07\/20\/lgmd-researcher-emerson\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lgmd-info.org\/de\/"},{"@type":"ListItem","position":2,"name":"LGMD RESEARCHER: Charles P. Emerson, Jr., Ph.D."}]},{"@type":"WebSite","@id":"https:\/\/www.lgmd-info.org\/de\/#website","url":"https:\/\/www.lgmd-info.org\/de\/","name":"LGMD Awareness Foundation","description":"Information Hub for the LGMD community","publisher":{"@id":"https:\/\/www.lgmd-info.org\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lgmd-info.org\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr-TR"},{"@type":"Organization","@id":"https:\/\/www.lgmd-info.org\/de\/#organization","name":"LGMD Awareness Foundation, Inc.","url":"https:\/\/www.lgmd-info.org\/de\/","logo":{"@type":"ImageObject","inLanguage":"tr-TR","@id":"https:\/\/www.lgmd-info.org\/de\/#\/schema\/logo\/image\/","url":"https:\/\/lgmd-info.org\/wp-content\/uploads\/2021\/02\/LGMD_Logo.png","contentUrl":"https:\/\/lgmd-info.org\/wp-content\/uploads\/2021\/02\/LGMD_Logo.png","width":208,"height":61,"caption":"LGMD Awareness Foundation, Inc."},"image":{"@id":"https:\/\/www.lgmd-info.org\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LGMDawareness\/","https:\/\/x.com\/LgmdAwareness","https:\/\/www.instagram.com\/lgmdawareness\/"]},{"@type":"Person","@id":"https:\/\/www.lgmd-info.org\/de\/#\/schema\/person\/007755074875959ad5503c1c969678c7","name":"dooley","image":{"@type":"ImageObject","inLanguage":"tr-TR","@id":"https:\/\/www.lgmd-info.org\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c87b3b784fd4c1975884b6c3eab282b5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c87b3b784fd4c1975884b6c3eab282b5?s=96&d=mm&r=g","caption":"dooley"},"sameAs":["https:\/\/live-lgmd-2021.pantheonsite.io"]}]}},"_links":{"self":[{"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/posts\/2109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/comments?post=2109"}],"version-history":[{"count":0,"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/posts\/2109\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/media?parent=2109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/categories?post=2109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lgmd-info.org\/tr\/wp-json\/wp\/v2\/tags?post=2109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}